Definitive Healthcare (NASDAQ:DH) Stock Rating Upgraded by Wall Street Zen

Definitive Healthcare (NASDAQ:DH) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Sunday.

A number of other brokerages have also weighed in on DH. Zacks Research raised shares of Definitive Healthcare from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 28th. Robert W. Baird set a $1.10 target price on Definitive Healthcare in a research note on Friday, May 8th. Barclays reduced their target price on Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating for the company in a research note on Monday, March 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Definitive Healthcare in a research note on Wednesday, June 3rd. Finally, Bank of America reissued an “underperform” rating and issued a $0.70 price objective on shares of Definitive Healthcare in a report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have issued a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $2.47.

Definitive Healthcare Stock Performance

Shares of Definitive Healthcare stock opened at $0.67 on Friday. The company has a 50 day moving average price of $0.81 and a 200 day moving average price of $1.23. The firm has a market capitalization of $71.08 million, a P/E ratio of -0.42, a PEG ratio of 11.02 and a beta of 1.33. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.81. Definitive Healthcare has a 52 week low of $0.62 and a 52 week high of $4.70.

Definitive Healthcare (NASDAQ:DH) last released its earnings results on Thursday, May 7th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.03. Definitive Healthcare had a negative net margin of 76.04% and a positive return on equity of 4.04%. The company had revenue of $55.93 million for the quarter, compared to the consensus estimate of $55.02 million. Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. Sell-side analysts expect that Definitive Healthcare will post 0.04 EPS for the current year.

Institutional Trading of Definitive Healthcare

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Irenic Capital Management LP purchased a new stake in shares of Definitive Healthcare in the first quarter worth about $71,000. Flywheel Private Wealth LLC purchased a new position in Definitive Healthcare during the first quarter valued at approximately $83,000. Schonfeld Strategic Advisors LLC purchased a new position in Definitive Healthcare during the fourth quarter valued at approximately $35,000. ExodusPoint Capital Management LP acquired a new position in Definitive Healthcare in the fourth quarter valued at approximately $47,000. Finally, HRT Financial LP acquired a new position in Definitive Healthcare in the fourth quarter valued at approximately $47,000. Institutional investors and hedge funds own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.